Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. (KDNY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
kdny · pe ratio · data through Dec 31, 2022
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Chinook Therapeutics, Inc. (KDNY) measures how much investors pay for each dollar of the company's trailing earnings. KDNY's current PE ratio of N/A is calculated by dividing its stock price of $40.39 by its TTM earnings per share of -$2.87.
Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31
PE Ratio History
2015 – 2022 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Chinook Therapeutics, Inc.You KDNY | $2.7B | N/A | — | -$2.87 |
 BELLUS Health Inc. BLU | $1.9B | N/A | — | -$0.66 |
 Calliditas Therapeutics AB (publ) CALT | $2.1B | N/A | — | -$17.37 |
 DICE Therapeutics, Inc. DICE | $2.3B | N/A | — | -$2.07 |
 Fusion Pharmaceuticals Inc. FUSN | $1.8B | N/A | — | -$1.45 |
 Longboard Pharmaceuticals, Inc. LBPH | $2.3B | N/A | — | -$2.39 |
 MorphoSys AG MOR | $2.9B | N/A | — | -$1.38 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2022-12-31Latest FY2022 | — | $-2.87 | — | |
2021-12-31 FY2021 | — | $-2.22 | — | |
2020-12-31 FY2020 | — | $-6.20 | — | |
2019-12-31 FY2019 | — | $-1.11 | — | |
2018-12-31 FY2018 | — | $-0.00 | — | |
2017-12-31 FY2017 | — | $-0.00 | — | |
2016-12-31 FY2016 | — | $-0.00 | — | |
2015-12-31 FY2015 | — | $-0.00 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Chinook Therapeutics, Inc. (KDNY) measures how much investors pay for each dollar of the company's trailing earnings. KDNY's current PE ratio of N/A is calculated by dividing its stock price of $40.39 by its TTM earnings per share of -$2.87.
Frequently asked questions
KDNY pe ratio · 6 questionsKDNY's current PE ratio is N/A as of 2026-06-09, based on a stock price of $40.39 and TTM EPS of -$2.87. Data sourced from Financial Modeling Prep via KDNY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Chinook Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09